{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:30:03Z","timestamp":1787319003640,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA219541"],"award-info":[{"award-number":["CA219541"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA226281"],"award-info":[{"award-number":["CA226281"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","cmghjournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.jcmgh.2024.101404","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T22:15:56Z","timestamp":1726265756000},"page":"101404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B\/\u03b2-catenin Pathway"],"prefix":"10.1016","volume":"19","author":[{"given":"Nianli","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-0153","authenticated-orcid":false,"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2024.101404_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jcmgh.2024.101404_bib2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma\u2014novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jcmgh.2024.101404_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","article-title":"Noncanonical functions of the polycomb group protein EZH2 in breast cancer","volume":"191","author":"Anwar","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41556-021-00653-6","article-title":"A\u00a0PRC2-independent function for EZH2 in regulating rRNA 2\u2032-O methylation and IRES-dependent translation","volume":"23","author":"Yi","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2024.101404_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcmgh.2024.101404_bib10","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb-and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcmgh.2024.101404_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41388-023-02618-5","article-title":"Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader","volume":"42","author":"Yu","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.jcmgh.2024.101404_bib12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib13","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1093\/nar\/gkac861","article-title":"A\u00a0cryptic transactivation domain of EZH2 binds AR and AR\u2019s splice variant, promoting oncogene activation and tumorous transformation","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcmgh.2024.101404_bib14","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.ajpath.2022.08.008","article-title":"EZH2 promotes cholangiocarcinoma development and progression through histone methylation and microRNA-mediated down-regulation of tumor suppressor genes","volume":"192","author":"Zhang","year":"2022","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib15","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.ajpath.2017.06.014","article-title":"Epigenetic silencing of miRNA-34a in human cholangiocarcinoma via EZH2 and DNA methylation: impact on regulation of notch pathway","volume":"187","author":"Kwon","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1502","article-title":"Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression","volume":"13","author":"Wu","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jcmgh.2024.101404_bib17","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1038\/s41467-023-40254-5","article-title":"Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39","volume":"14","author":"Campagne","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2024.101404_bib18","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/bph.15331","article-title":"RNA-binding motif protein 39 (RBM39): an emerging cancer target","volume":"179","author":"Xu","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbrc.2016.03.108","article-title":"Functional interaction between nonreceptor tyrosine kinase c-Abl and SR-Rich protein RBM39","volume":"473","author":"Mai","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jcmgh.2024.101404_bib20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1074\/jbc.M110417200","article-title":"Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors","volume":"277","author":"Jung","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2024.101404_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109156","article-title":"Inhibiting an RBM39\/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation","volume":"35","author":"Puvvula","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcmgh.2024.101404_bib22","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/j.molcel.2022.06.003","article-title":"An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma","volume":"82","author":"Zhou","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2024.101404_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj5405","article-title":"Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models","volume":"7","author":"Singh","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.jcmgh.2024.101404_bib24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"Nijhuis","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2024.101404_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113307","article-title":"Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcmgh.2024.101404_bib26","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","article-title":"Arginine reprograms metabolism in liver cancer via RBM39","volume":"186","author":"Mossmann","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2024.101404_bib27","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1111\/jcmm.17517","article-title":"Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker","volume":"26","author":"Zhang","year":"2022","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jcmgh.2024.101404_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2024.101404_bib29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-022-02394-2","article-title":"The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease","volume":"41","author":"Cigliano","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.101404_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13072-018-0242-9","article-title":"EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation","volume":"11","author":"Mu","year":"2018","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.jcmgh.2024.101404_bib31","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-16-2020","article-title":"Alternative splicing of EZH2 pre-mRNA by SF3B3 contributes to the tumorigenic potential of renal cancer","volume":"23","author":"Chen","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.101404_bib32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI76452","article-title":"WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited","volume":"125","author":"Boulter","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2024.101404_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/1078-0432.CCR-18-0284","article-title":"Combined CDK4\/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.101404_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jcmgh.2024.101404_bib35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.celrep.2018.09.041","article-title":"RBM17 interacts with U2SURP and CHERP to regulate expression and splicing of RNA-processing proteins","volume":"25","author":"De Maio","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcmgh.2024.101404_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188700","article-title":"EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy","volume":"1877","author":"Sun","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.jcmgh.2024.101404_bib37","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood.2022015668","article-title":"Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","volume":"140","author":"Poplineau","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcmgh.2024.101404_bib38","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1038\/onc.2015.331","article-title":"NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2","volume":"35","author":"De Donatis","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.jcmgh.2024.101404_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107115","article-title":"An EZH2-NF-\u03baB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer","volume":"26","author":"Dardis","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.jcmgh.2024.101404_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303010120","article-title":"Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways","volume":"120","author":"Liu","year":"2023","journal-title":"Proc Nat Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2024.101404_bib41","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/0008-5472.CAN-10-3342","article-title":"EZH2-mediated concordant repression of Wnt antagonists promotes \u03b2-catenin\u2013dependent hepatocarcinogenesis","volume":"71","author":"Cheng","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.101404_bib42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.gastro.2012.03.045","article-title":"MicroRNA-26a promotes cholangiocarcinoma growth by activating \u03b2-catenin","volume":"143","author":"Zhang","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2024.101404_bib43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2022.04.028","article-title":"\u03b2-Catenin sustains and is required for YES-associated protein oncogenic activity in cholangiocarcinoma","volume":"163","author":"Zhang","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2024.101404_bib44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/cells12081141","article-title":"Impact of aberrant \u03b2-catenin pathway on cholangiocarcinoma heterogeneity","volume":"12","author":"Lozano","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jcmgh.2024.101404_bib45","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1007\/s13277-014-1698-2","article-title":"Activated macrophages promote Wnt\/\u03b2-catenin signaling in cholangiocarcinoma cells","volume":"35","author":"Loilome","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.jcmgh.2024.101404_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13046-023-02844-5","article-title":"The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression","volume":"42","author":"Liu","year":"2023","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jcmgh.2024.101404_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X24001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X24001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T02:04:21Z","timestamp":1734314661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X24001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2352345X24001590"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2024.101404","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B\/\u03b2-catenin Pathway","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2024.101404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"101404"}}